The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...
The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers. Congress created ...
Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter ...
The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...
On July 31, 2025, the Health Resources and Services Administration (HRSA) published a notice in the Federal Register (Rebate Model Notice) announcing a 340B Rebate Model Pilot Program (Pilot Program).
The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states ...
More than 1,100 hospitals have sent a letter to Health and Human Services Secretary Alex Azar demanding that the department enforce 340B drug pricing requirements. In recent weeks several major ...
Hospitals that serve a high volume of low-income and uninsured patients rely on Disproportionate Share Hospital (DSH) funding to maintain financial stability. A hospital’s DSH percentage is critical ...
More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
The number of 340B providers has grown from about 10,000 to 66,000 in the past 15 years, while the number of contract pharmacies increased from 1,300 to 253,000 over the same time. The dramatic growth ...
Hosted on MSN
Reform of federal drug discount program should target misaligned incentives, researchers say
The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers. Subscribe to our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback